IOM: Wide Gaps in FDA Drug-Safety Process
Posted on: Friday, 22 September 2006, 18:00 CDT
The U.S. Food and Drug Administration's process for ensuring the safety of marketed drugs is taken to task in a new government report.
In its highly anticipated critique of the FDA's drug-safety process released Friday, the Institute of Medicine said that thin funding, an ineffective organizational structure and weak enforcement muscle are all contributing to a less than optimal process to minimize the health risks of drugs the agency approves for market.
The IOM report particular zeroed in on the stage at which drugs are released into the marketplace and being prescribed in patients as an especially weak link in the drug-safety chain, noting that resources and therefore efforts to monitor medications' risk-benefit profiles taper off after approval.
In the wake of recent safety scandals such as the recall of Merck's painkiller Vioxx after an increased cardiac risk was seen in patients taking the drug long term and a troubling rise in suicidal behaviors in children taking prescription anti-depressants, FDA critics said the agency had a conflict in approving drugs for market then later having to second-guess its own decisions by monitoring drug safety at the post-market phase, and called for a separate body to oversee drug safety of marketed products.
IOM also found there is a perception of crisis that has compromised the credibility of FDA and of the pharmaceutical industry and that the two sectors do not consistently demonstrate accountability and transparency to the public by communicating safety concerns in a timely and effective fashion.
To address these concerns, the report advised:
-- Labeling requirements and advertising limits for new medications.
-- Clarified authority and additional enforcement tools for the agency.
-- Clarification of the FDA's role in gathering and communicating additional information on marketed products' risks and benefits.
-- Mandatory registration of clinical-trial results to facilitate public access to drug-safety information.
-- An increased role for the FDA's drug-safety staff.
-- A large boost in funding and staffing for the agency.
Source: United Press International
Related Articles
- ThromboVision Completes T-Guide(R) Clinical Trials; Files With the FDA for Clearance to Market
- Sorin Group: Announces U.S. FDA's Approval to Market Its Mitroflow Aortic Pericardial Heart Valve in the United States
- FDA Approves Drug for Disease Once Dismissed As `Yuppie Flu'
- Research and Markets: Antibiotics and Drug Resistance 2007 - Drug Innovation and the Strategy to Combat Antibiotic Resistance Mechanisms
- FDA Approves Drug to Prevent Hepatitis B Reinfection in Liver Transplant Patients
- Antisense Oligonucleotides Have Been in Clinical Trials for Cancer for Some Time Now - Drug Delivery in Cancer - Technologies, Markets and Companies Report 2007
- Drug Makers Fail to Begin 71% of Promised Studies of Drugs Already Approved for the Market
- FDA Approves Drug for Autism Irritability
- FDA: MS Drug Tysabri Can Return to Market
- FDA Criticized Over Post-Market Drug Safety Problems
User Comments (0)
RSS Feeds